🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease brnw.ch/21wLDHK

On the Strength of a Recommendation: ascopubs.org/doi/abs/10.120…

Optimizing next-gen sequencing in #Urothelial cancer - #Expert #Consensus recommendations! Andrea Necchi and Ashish M. Kamat, MD, MBBS underscore the need for careful tissue mgmt, recommending NGS especially when clinical trial opportunities are present. #WatchNow > bit.ly/46HB8nJ

Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer brnw.ch/21wLQOA

Testicular Germ Cell Tumors with Venous Tumor Thrombus: Prevalence, Presentation, and Management Eur Urol Focus Sarah P. Psutka MD MS Philippe spiess Global Society of Rare GU Tumors eu-focus.europeanurology.com/article/S2405-…

Cannabis for Refractory Chemotherapy-Induced Nausea and Vomiting: the applicability and generalizability of the evidence is limited by changes in antiemetic guidelines and availability of THC:CBD. Thoughtful Journal of Clinical Oncology editorial by Dr Zimmermann ascopubs.org/doi/full/10.12…

📢Calling all oncology researchers! We’re accepting submissions for JCO Oncology Advances. Share impactful cancer research with a global community and contribute to advancing clinical oncology. Submit your work ➡️ brnw.ch/21wM6Ts #JCO #OncologyResearch #OpenAccess

MRI should be a routine for daily management of MIBC. cCR definition and modern bladder-sparing strategies will rely on it. Congratulations a step forward to this direction

What’s the difference between urachal and nonurachal adenocarcinoma the bladder? You may take a look of this most recent paper published this month in JCO Precision Oncology JCO Precision Oncology This important study, led by Dr. Andea Necchi Andrea Necchi, represents the largest cohort

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer. Watch Dr Antonio Cigliola discuss the SURE-01/02 study👉 bit.ly/3AZkofG Ospedale San Raffaele #ASCO2024

Enhancing Precision in Detecting Severe Immune-Related Adverse Events: use of large language models required 9 seconds/chart versus 15 minutes for clinician adjudication and demonstrated higher sensitivity with similar specificity. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Huge congrats to prof. Andrea Necchi and all the team, stellar first author Chiara Mercinelli and my partner in crime Laura Cogrossi